A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?

Rosselló, Xavier; Yellon, Derek M.

doi:10.1016/j.ijcard.2016.11.246

Cited by 9 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…88 The potential protective effect provided by the new SGLT2 inhibitors remains largely unknown at the moment, but it might become a new potential target to limit myocardial IS in AMI patients. 89 N-acetylcysteine. The cardioprotective effect of N-acetylcysteine (NAC), a sulfhydryl-containing antioxidant agent, has been widely tested in both the experimental and clinical setting, with some controversial results.…”

Section: Pharmacological Strategiesmentioning

confidence: 99%

See 1 more Smart Citation

Editor’s Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome

Rosselló

Lobo-González

Ibáñez

2019

European Heart Journal: Acute Cardiovascular Care

Self Cite

View full text Add to dashboard Cite

There is a need to find interventions able to reduce the extent of injury in reperfused ST-segment elevation myocardial infarction (STEMI) beyond timely reperfusion. In this review, we summarise the clinical impact of STEMI from epidemiological, clinical and biological perspectives. We also revise the pathophysiology underlying the ischaemia/reperfusion syndrome occurring in reperfused STEMI, including the several players involved in this syndrome, such as cardiomyocytes, microcirculation and circulating cells. Interventions aimed to reduce the resultant infarct size, known as cardioprotective therapies, are extensively discussed, putting the focus on both mechanical interventions (i.e. ischaemic conditioning) and promising pharmacological therapies, such as early intravenous metoprolol, exenatide and other glucose modulators, N-acetylcysteine as well as on some other classic therapies which have failed to be translated to the clinical arena. Novel targets for evolving therapeutic interventions to ameliorate ischaemia/reperfusion injury are also discussed. Finally, we highlight the necessity to improve the study design of future randomised clinical trials in the field, as well as to select patients better who can most likely benefit from cardioprotective interventions.

show abstract

Section: Pharmacological Strategiesmentioning

confidence: 99%

Section: Cardioprotective Interventions Beyond Reperfusionmentioning

confidence: 99%

Editor’s Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome

Rosselló

Lobo-González

Ibáñez

2019

European Heart Journal: Acute Cardiovascular Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…One of these substrates is GLP-1, and there has been much interest in the potential pleotropic actions of GLP-1 analogs. This interest in GLP-1 was based on the findings of a number of large clinical trials showing that these agents provide cardiovascular risk benefits to T2DM patients beyond those that can be explained through their effects on glycemic control or weight loss alone (82)(83)(84)(85)(86)(87)(88)(89)(90). Indeed, in addition to the use of GLP-1 analogs as insulin-sensitizing therapies in insulin-resistant patients at risk of CVD, they are now being used to induce weight loss as a treatment for obesity and have been shown to induce brown remodeling of WAT in a sirtuin 1 (Sirt1)-dependent manner (86,91,92).…”

Section: Antidiabetic Agentsmentioning

confidence: 99%

Adipose Tissue in Cardiovascular Disease: From Basic Science to Clinical Translation

Polkinghorne,

West,

Antoniades

2024

Annu. Rev. Physiol.

View full text Add to dashboard Cite

The perception of adipose tissue as a metabolically quiescent tissue, primarily responsible for lipid storage and energy balance (with some endocrine, thermogenic, and insulation functions), has changed. It is now accepted that adipose tissue is a crucial regulator of metabolic health, maintaining bidirectional communication with other organs including the cardiovascular system. Additionally, adipose tissue depots are functionally and morphologically heterogeneous, acting not only as sources of bioactive molecules that regulate the physiological functioning of the vasculature and myocardium but also as biosensors of the paracrine and endocrine signals arising from these tissues. In this way, adipose tissue undergoes phenotypic switching in response to vascular and/or myocardial signals (proinflammatory, profibrotic, prolipolytic), a process that novel imaging technologies are able to visualize and quantify with implications for clinical prognosis. Furthermore, a range of therapeutic modalities have emerged targeting adipose tissue metabolism and altering its secretome, potentially benefiting those at risk of cardiovascular disease. Expected final online publication date for the Annual Review of Physiology, Volume 86 is February 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

show abstract

“…In 2019, the DAPA-HF trial showed a substantial clinical benefit of dapagliflozin among patients with heart failure and reduced ejection fraction, regardless of the presence or absence of diabetes. 1 For many people, this trial was a breaking point after years of speculation: 2 SGLT2 inhibitors became not only a good medication for diabetes but also an excellent drug for cardiovascular disease. About half a year after the publication of the DAPA-HF, COVID-19 was characterised as a pandemic by WHO.…”

mentioning

confidence: 99%

Dapagliflozin in patients with COVID-19: truth or dare

Rosselló

Caimari

2021

The Lancet Diabetes & Endocrinology

Self Cite

View full text Add to dashboard Cite

A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?

Cited by 9 publications

References 14 publications

Editor’s Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome

Editor’s Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome

Adipose Tissue in Cardiovascular Disease: From Basic Science to Clinical Translation

Dapagliflozin in patients with COVID-19: truth or dare

Contact Info

Product

Resources

About